1 / 1

FAIR-HF

FAIR-HF. Primary outcome, Patient Global Assessment at 24 weeks: Much or moderately improved in 50% of the intravenous iron group vs. 28% of the placebo group (p < 0.001) New York Heart Association (NYHA) class I or II at 24 weeks: 47% vs. 30% (p < 0.001) Death: 3.4% vs. 5.5% (p = 0.47)

boyd
Download Presentation

FAIR-HF

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FAIR-HF Primary outcome, Patient Global Assessment at 24 weeks: Much or moderately improved in 50% of the intravenous iron group vs. 28% of the placebo group (p < 0.001) New York Heart Association (NYHA) class I or II at 24 weeks: 47% vs. 30% (p < 0.001) Death: 3.4% vs. 5.5% (p = 0.47) Hospitalization for any cardiovascular cause: 10.4% vs. 20.0% (p = 0.08) Trial design: Patients with chronic heart failure and iron deficiency (with or without anemia) were randomized to intravenous iron (ferric carboxymaltose) (n = 304) vs. placebo (n = 155) for 24 weeks. Results (p < 0.001) (p < 0.001) % Conclusions • Among patients with chronic heart failure and iron deficiency, the use of intravenous iron for 24 weeks was beneficial • This therapy resulted in improved symptoms and functional capacity • Intravenous iron appeared to be safe Much or moderately improved patient assessment NYHA class I or II Intravenous iron Placebo Anker SD, et al. N Engl J Med 2009;Nov 17:[Epub]

More Related